Phase II randomised proof-of-concept study of the urokinase inhibitor upamostat (WX-671) in combination with gemcitabine compared with gemcitabine alone in patients with non-resectable, locally advanced pancreatic cancer

Phase II randomised proof-of-concept study of the urokinase inhibitor upamostat (WX-671) in combination with gemcitabine compared with gemcitabine alone in patients with non-resectable, locally advanced pancreatic cancer

Item

http://www.wikidata.org/entity/Q36663677

Q36663677

about

Influence of Immune Myeloid Cells on the Extracellular Matrix During Cancer Metastasis Molecular Targeted Intervention for Pancreatic Cancer Candidate prognostic markers in breast cancer: focus on extracellular proteases and their inhibitors Visceral hypersensitivity in inflammatory bowel diseases and irritable bowel syndrome: The role of proteases Selected hemostatic parameters in patients with pancreatic tumors.uPA and PAI-1 as biomarkers in breast cancer: validated for clinical use in level-of-evidence-1 studies.Progression of Osteosarcoma from a Non-Metastatic to a Metastatic Phenotype Is Causally Associated with Activation of an Autocrine and Paracrine uPA Axis.A novel uPAg-KPI fusion protein inhibits the growth and invasion of human ovarian cancer cells in vitro Involvement of urokinase-type plasminogen activator system in cancer: an overview.Recent advances on plasmin inhibitors for the treatment of fibrinolysis-related disorders.Brief overview of selected approaches in targeting pancreatic adenocarcinoma.Hispolon suppresses migration and invasion of human nasopharyngeal carcinoma cells by inhibiting the urokinase-plasminogen activator through modulation of the Akt signaling pathway.The role of type II transmembrane serine protease-mediated signaling in cancer.The Role of Consolidation Chemo-Radiotherapy in Locally Advanced Pancreatic Cancer Receiving Chemotherapy: An Updated Systematic Review and Meta-Analysis.Urokinase-type plasminogen activator receptor (uPAR) expression enhances invasion and metastasis in RAS mutated tumors.American Society of Clinical Oncology highlights 2013: breast cancer and gynecological malignancies.Identification of cancer genes that are independent of dominant proliferation and lineage programs.The fibrinolysis inhibitor α2-antiplasmin restricts lymphatic remodelling and metastasis in a mouse model of cancer.Urokinase-type plasminogen activator (uPA) is critical for progression of tuberous sclerosis complex 2 (TSC2)-deficient tumors.Deregulated hepsin protease activity confers oncogenicity by concomitantly augmenting HGF/MET signalling and disrupting epithelial cohesion.

P2860

Q26767150-5D565C97-F47D-4E07-94B2-E9FA0E1F9BDD Q26798453-CFCD2081-5BF7-4302-9D78-83BCE562D787 Q26830522-88F743E1-2609-420E-9115-28937332B8B2 Q28818844-159AB76B-2430-4D3A-AC82-A946AA63D687 Q34978795-FB2E47CA-550E-4EB2-A4CA-8D3618BAF81D Q35580701-2508F33B-F062-4C82-ABE5-EF3F7CDBCC63 Q35758432-14FE6385-B073-4FE3-8C5D-3F8ED6AB1AD2 Q36791190-52390EF8-0377-4485-9B10-2A91552177A1 Q38189275-F147B61A-DD60-4A39-93A2-7D34C8059D22 Q38198582-288124AC-A5D6-45BB-85C6-6D8B6EFEEAF8 Q38199723-2AD74EAC-337E-473B-88C9-D5B33E3BC26E Q38781428-9F46359D-934A-4F3F-B890-E88F6B18137E Q39015415-404B007D-BCE5-49C0-9DC6-00F6C1635068 Q39364761-9BB49AC0-DFD1-4F02-8EBE-3DE5644AE788 Q41518094-FC0C2563-0CF2-44E0-A47F-8A13400B7885 Q44246406-B0F85FA6-D47B-4D5B-A3A9-5475DA49734E Q47327357-5EEBF11F-A6F7-49D7-BB02-DE075A725C4C Q50896878-9695283F-F364-439F-9DA2-93F2B4C9CCB5 Q51779283-994E2D4A-9A6F-4FBD-86EB-044ABEED1F4C Q52661781-4E9681FF-93C1-4597-B87C-208F2D18121C

P2860

Phase II randomised proof-of-concept study of the urokinase inhibitor upamostat (WX-671) in combination with gemcitabine compared with gemcitabine alone in patients with non-resectable, locally advanced pancreatic cancer

Item

http://www.wikidata.org/entity/Q36663677

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

2013年论文

@zh

2013年论文

@zh-cn

name

Phase II randomised proof-of-c ...... lly advanced pancreatic cancer

@ast

Phase II randomised proof-of-c ...... lly advanced pancreatic cancer

@en

type

Item

label

Phase II randomised proof-of-c ...... lly advanced pancreatic cancer

@ast

Phase II randomised proof-of-c ...... lly advanced pancreatic cancer

@en

prefLabel

Phase II randomised proof-of-c ...... lly advanced pancreatic cancer

@ast

Phase II randomised proof-of-c ...... lly advanced pancreatic cancer

@en

P1476

Phase II randomised proof-of-c ...... lly advanced pancreatic cancer

@en

P2093

C Mala

http://www.w3.org/2001/XMLSchema#string

M P Ebert

http://www.w3.org/2001/XMLSchema#string

P Bevan

http://www.w3.org/2001/XMLSchema#string

R P Laubender

http://www.w3.org/2001/XMLSchema#string

S Boeck

http://www.w3.org/2001/XMLSchema#string

V Heinemann

http://www.w3.org/2001/XMLSchema#string

P2860

Pancreatic cancer treatment and research: an international expert panel discussion.

DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer.

The Oral Serine Protease Inhibitor WX-671 - First Experience in Patients with Advanced Head and Neck Carcinoma.

Interference with the urokinase plasminogen activator system: a promising therapy concept for solid tumours.

Phase II trial of cetuximab, gemcitabine, and oxaliplatin followed by chemoradiation with cetuximab for locally advanced (T4) pancreatic adenocarcinoma: correlation of Smad4(Dpc4) immunostaining with pattern of disease progression.

Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial.

The urokinase plasminogen activator system: a target for anti-cancer therapy.

Systemic treatment of advanced pancreatic cancer.

Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1.

The uPA/uPA receptor system as a target for tumor therapy.

P2888

bjc.2013.62

P304

766-770

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/BJC.2013.62

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

108

http://www.w3.org/2001/XMLSchema#string

P577

2013-02-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

235629322

http://www.w3.org/2001/XMLSchema#string

P698

23412098

http://www.w3.org/2001/XMLSchema#string

P932

3590684

http://www.w3.org/2001/XMLSchema#string

Phase II randomised proof-of-concept study of the urokinase inhibitor upamostat (WX-671) in combination with gemcitabine compared with gemcitabine alone in patients with non-resectable, locally advanced pancreatic cancer

about

P2860

P2860

Phase II randomised proof-of-concept study of the urokinase inhibitor upamostat (WX-671) in combination with gemcitabine compared with gemcitabine alone in patients with non-resectable, locally advanced pancreatic cancer

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P407

P433

P478

P577

P5875

P698

P932

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P407

P433

P478

P577

P5875

P698

P932